Strong Start to the Year 2025
Hemostemix (TSXV:HEM; FRA:2VF0) has placed treatments worth $400,000 USD in January 2025 alone since the start of pre-sales for its ACP-01 stem cell therapy. The new patients were generated through a social media campaign and presentations in Puerto Rico. Through the pre-sales of ACP-01, buyers/patients secure early positions on the list for their therapy. By booking early, patients gain the assurance that their treatment is firmly scheduled and when it is expected to take place.
Thomas Smeenk, CEO of Hemostemix commented: “The pre-sales allow Hemostemix to plan for physician time and production time. Our numbers are still modest at present, but the first signed commitments amount to about $400,000 USD, which is a good start for 2025, considering we have 11 months ahead of us.”
The feedback on the Hemostemix therapy that he receives from some treating physicians is overwhelming, Smeenk said: “In my meetings this week with doctors who have treated about 200 patients so far, I am impressed by their response to the same question I ask every doctor I meet who has used ACP-01: ‘Tell me about your patients and what you have observed regarding your patients’ outcomes?’ Yesterday, an invasive cardiologist who has treated 200 patients with ACP in a team of three cardiologists told me: ‘I have used many stem cell products. ACP-01 in the heart is unbeatable; it restores heart function. That is unique. No other autologous stem cells work like ACP-01.'”
